A single systemic injection of AAV9-hIGFBP2 prevents left ventricular hypertrophy and dysfunction in metabolic syndrome

ConclusionHuman plasma and cardiac IGFBP2 are decreased in MetS patients. In mice, restoration of cardiac IGFBP2 expression level prevents MetS associated left ventricular dysfunction and hypertrophy. These clinical and animal data suggest that IGFBP2 is a new cardiac marker and therapeutic target in MetS to prevent heart remodeling consistent with heart failure.
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research